ATE20517T1 - Theophyllintablette mit kontrollierter wirkstoffabgabe und verfahren zu deren herstellung. - Google Patents

Theophyllintablette mit kontrollierter wirkstoffabgabe und verfahren zu deren herstellung.

Info

Publication number: ATE20517T1
Authority: AT; Austria
Prior art keywords: weight; ratio; tablet; polymer; theophyllin
Prior art date: 1982-11-03

Application number

AT83402073T

Other languages

English (en)

Inventor

Joel Bougaret

Daniel Darbeau

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-03

Filing date

1983-10-25

Publication date

1986-07-15

1983-10-25 Application filed by Pf Medicament filed Critical Pf Medicament

1986-07-15 Application granted granted Critical

1986-07-15 Publication of ATE20517T1 publication Critical patent/ATE20517T1/de

Links

ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title abstract 5
229960000278 theophylline Drugs 0.000 title abstract 4
238000013270 controlled release Methods 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
229920000642 polymer Polymers 0.000 abstract 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
239000000314 lubricant Substances 0.000 abstract 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
229920002678 cellulose Polymers 0.000 abstract 1
239000001913 cellulose Substances 0.000 abstract 1
230000036571 hydration Effects 0.000 abstract 1
238000006703 hydration reaction Methods 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
238000011287 therapeutic dose Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AT83402073T 1982-11-03 1983-10-25 Theophyllintablette mit kontrollierter wirkstoffabgabe und verfahren zu deren herstellung. ATE20517T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8218407A FR2535202B1 (fr)	1982-11-03	1982-11-03	Comprimes de theophylline a liberation controlee et leur procede de fabrication
EP83402073A EP0109320B1 (de)	1982-11-03	1983-10-25	Theophyllintablette mit kontrollierter Wirkstoffabgabe und Verfahren zu deren Herstellung

Publications (1)

Publication Number	Publication Date
ATE20517T1 true ATE20517T1 (de)	1986-07-15

Family

ID=9278859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT83402073T ATE20517T1 (de)	1982-11-03	1983-10-25	Theophyllintablette mit kontrollierter wirkstoffabgabe und verfahren zu deren herstellung.

Country Status (8)

Country	Link
EP (1)	EP0109320B1 (de)
AT (1)	ATE20517T1 (de)
CA (1)	CA1205385A (de)
DE (1)	DE3364276D1 (de)
ES (1)	ES526928A0 (de)
FR (1)	FR2535202B1 (de)
PT (1)	PT77581B (de)
ZA (1)	ZA838058B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA836031B (en) *	1983-08-16	1985-02-27	Verex Lab	Constant release rate solid dosage theophylline formulation
FR2585948B1 (fr) *	1985-08-06	1988-12-16	Pf Medicament	Procede de fabrication de comprimes d'indometacine
FR2588188B1 (fr) *	1985-10-04	1988-01-08	Delalande Sa	Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
GB8628728D0 (en) *	1986-12-02	1987-01-07	Euro Celtique Sa	Spheroids
FR2618073B1 (fr) *	1987-07-16	1990-09-07	Pf Medicament	Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
GB8813064D0 (en) *	1988-06-02	1988-07-06	Euro Celtique Sa	Controlled release dosage forms having defined water content
US5268181A (en) *	1989-04-13	1993-12-07	Upsher-Smith Laboratories, Inc.	Method of using niacin to control nocturnal cholesterol synthesis
US6676967B1 (en)	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en)	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en)	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US5484607A (en) *	1993-10-13	1996-01-16	Horacek; H. Joseph	Extended release clonidine formulation
US5393765A (en) *	1993-12-13	1995-02-28	Hoffmann-La Roche Inc.	Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6197340B1 (en)	1998-05-28	2001-03-06	Medical Research Institute	Controlled release lipoic acid
WO2003011256A1 (en) *	2001-07-30	2003-02-13	Sun Pharmaceutical Industries Limited	Oral controlled release pharmaceutical composition of a prokinetic agent
ATE538797T1 (de) *	2005-06-09	2012-01-15	Euro Celtique Sa	Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
AU2008261957A1 (en)	2007-06-08	2008-12-18	Addrenex Pharmaceuticals, Inc.	Extended release formulation and method of treating adrenergic dysregulation
EP2937096B1 (de)	2014-04-23	2019-08-21	Julius-Maximilians-Universität Würzburg	Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2050701C3 (de) *	1969-10-17	1979-12-20	Shinetsu Chemical Co., Tokio	Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen
JPS4917565B1 (de) *	1970-12-29	1974-05-01
AT347039B (de) *	1972-11-03	1978-12-11	Ohrenberger Franz X Dr	Verfahren zur herstellung von tabletten und dragees mit einem gehalt an zwei verschiedenen heilmittelwirkstoffen mit verzoegerter wirk- stoffabgabe
JPS55153715A (en) *	1979-05-18	1980-11-29	Nikken Kagaku Kk	Prolonged granule of theophylline
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
JPS56122311A (en) *	1980-02-29	1981-09-25	Eisai Co Ltd	Lasting theophylline pharmaceutical composition

1982
- 1982-11-03 FR FR8218407A patent/FR2535202B1/fr not_active Expired
1983
- 1983-10-25 DE DE8383402073T patent/DE3364276D1/de not_active Expired
- 1983-10-25 AT AT83402073T patent/ATE20517T1/de not_active IP Right Cessation
- 1983-10-25 EP EP83402073A patent/EP0109320B1/de not_active Expired
- 1983-10-28 PT PT77581A patent/PT77581B/pt unknown
- 1983-10-28 ZA ZA838058A patent/ZA838058B/xx unknown
- 1983-10-31 ES ES526928A patent/ES526928A0/es active Granted
- 1983-11-02 CA CA000440229A patent/CA1205385A/fr not_active Expired

Also Published As

Publication number	Publication date
FR2535202A1 (fr)	1984-05-04
ES8405618A1 (es)	1984-07-01
PT77581B (fr)	1986-03-18
ZA838058B (en)	1984-06-27
EP0109320B1 (de)	1986-06-25
ES526928A0 (es)	1984-07-01
PT77581A (fr)	1983-11-01
FR2535202B1 (fr)	1985-08-09
EP0109320A1 (de)	1984-05-23
CA1205385A (fr)	1986-06-03
DE3364276D1 (en)	1986-07-31

Similar Documents

Publication	Publication Date	Title
ATE20517T1 (de)	1986-07-15	Theophyllintablette mit kontrollierter wirkstoffabgabe und verfahren zu deren herstellung.
DE69316023T2 (de)	1998-04-23	Stabile zusammensetzung für eine orale dosis mit verlängerter freisetzung
AU616449B2 (en)	1991-10-31	Controlled release combination of carbidopa/levodopa
DE642785T1 (de)	1995-09-28	Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe.
US4900755A (en)	1990-02-13	Controlled release combination of carbidopa/levodopa
ES2065461T5 (es)	2001-01-01	Unidades de administracion de un farmaco de liberacion constante.
US4983400A (en)	1991-01-08	Controlled release combination of carbidopa/levodopa
NO149490B (no)	1984-01-23	Fremgangsmaate ved fremstilling av tabletter med regulert frigjoerelse av den aktive bestanddel
CA2041774A1 (en)	1992-05-28	Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
AU1358695A (en)	1995-06-01	Nasal administration
NO167360C (no)	1991-10-30	Tverrbundede, poroese polymerer for regulert legemiddelavgivning.
SE8405615D0 (sv)	1984-11-09	Sustained release pharmaceutical tablets and process for the preparation thereof
PT92069A (pt)	1990-04-30	Processo para a producao de um sistema de distribuicao de drogas
NO176232C (no)	1995-03-01	Fremgangsmåte for fremstilling av en fast, oral doseringsform med regulert frigivelse av medikament
ATE246505T1 (de)	2003-08-15	Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix
DE69706748T2 (de)	2002-07-04	Oral anzuwendende Matrixtabletten mit verzögerter Wirkstoffabgabe enthaltend Tianeptin Natriumsalz
ITMI922826A1 (it)	1994-06-11	Composizione farmaceutica a rilascio controllato in sospensione liquida
DE3367324D1 (en)	1986-12-11	Pharmaceutical products in sustained-release form, and their preparation process
TNSN90021A1 (fr)	1991-03-05	Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
ATE172112T1 (de)	1998-10-15	Verfahren zur herstellung eines retardpräparates, das diltiazem in einer einzigen tagesdosis enthält
DE2520978C3 (de)	1981-02-19	Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
EP0374096A1 (de)	1990-06-20	2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
EP3335700A1 (de)	2018-06-20	Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron
DE69420266T2 (de)	1999-12-09	Rektale zusammensetzungen enthaltend odansetron als freie base
KR880004810A (ko)	1988-06-27	소화성 궤양 치료제

Legal Events

Date	Code	Title	Description
1986-12-15	UEP	Publication of translation of european patent specification
2004-01-15	EELA	Cancelled due to lapse of time